EUVIMEDEUVIMED entdecken
Crossref

Class 1C Antiarrhythmics for Premature Ventricular Complex Suppression in Nonischemic Cardiomyopathy With Implantable Cardioverter-Defibrillators

Mohamad Raad, Haran Yogasundaram, Justice Oranefo, Gustavo Guandalini, Timothy Markman, Matthew Hyman, Robert Schaller, Gregory Supple, Rajat Deo, Saman Nazarian, Michael Riley, David Lin und 6 weitere

JACC: Clinical Electrophysiology · 2024

DOI: 10.1016/j.jacep.2024.01.021 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JACC: Clinical Electrophysiology, 2024. Verfasst von Mohamad Raad und 17 weiteren Autor:innen. Beteiligte Einrichtung: Electrophysiology Section, Division of Cardiovascular Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylv…. Hauptthemen laut MEDLINE: Anti-Arrhythmia Agents, Cardiomyopathies, Defibrillators, Implantable, Ventricular Premature Complexes. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Premature ventricular complexes (PVCs) are common and associated with worse outcomes in patients with heart failure. Class 1C antiarrhythmic drugs (AADs) effectively suppress PVCs, but guidelines currently restrict their use in structural heart disease. OBJECTIVES: This study aimed to assess the safety and efficacy of class 1C AADs in patients with nonischemic cardiomyopathy (NICM) and implantable cardioverter-defibrillators (ICDs). METHODS: All patients with NICM and an ICD treated with flecainide or propafenone at the Hospital of the University of Pennsylvania between 2014 and 2022 were identified. PVC burden, left ventricular ejection fraction (LVEF), and biventricular pacing percentage were compared before and during class 1C AAD treatment. Safety outcomes included sustained atrial and ventricular arrhythmias, heart failure admissions, and death. RESULTS: We identified 34 patients, 23 receiving flecainide and 11 propafenone. Most patients (62%) had failed other AADs or catheter ablation (68%) prior to class 1C AAD initiation. PVC burden decreased from 20% ± 13% to 6% ± 7% (P < 0.001), LVEF increased from 33% ± 9% to 37% ± 10% (P = 0.01), and biventricular pacing percentage increased from 85% ± 9% to 93% ± 7% (P = 0.01). Sustained ventricular tachycardia (2 vs 9 patients) and admissions for decompensated heart failure (2 vs 3 patients) decreased compared with the 12 months prior to class 1C AAD initiation. CONCLUSIONS: Class 1C AADs effectively suppressed PVCs in patients with NICM and ICDs, leading to increases in LVEF and biventricular pacing percentage. In this limited sample, their use was safe. Larger studies are needed to confirm the safety of this approach.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Arrhythmia AgentsCardiomyopathiesDefibrillators, ImplantableVentricular Premature ComplexesFlecainideHumansMaleFemaleMiddle AgedAgedPropafenoneRetrospective StudiesStroke VolumeTreatment Outcome

Stichwörter der Autor:innen

class 1C antiarrhythmic drugsimplantable cardioverter-defibrillatornonischemic cardiomyopathypremature ventricular complexes

Substanzen

Anti-Arrhythmia AgentsFlecainidePropafenone

Autor:innen und Institutionen

  • Electrophysiology Section, Division of Cardiovascular Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Electrophysiology Section, Division of Cardiovascular Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA. Electronic address: david.frankel@pennmedicine.upenn.edu.

Zitieren

APA

Raad, M., Yogasundaram, H., Oranefo, J., Guandalini, G., Markman, T., Hyman, M., Schaller, R., Supple, G., Deo, R., Nazarian, S., Riley, M., Lin, D., Garcia, F., Dixit, S., Epstein, A. E., Callans, D., Marchlinski, F. E., & Frankel, D. S. (2024). Class 1C Antiarrhythmics for Premature Ventricular Complex Suppression in Nonischemic Cardiomyopathy With Implantable Cardioverter-Defibrillators. JACC: Clinical Electrophysiology. https://doi.org/10.1016/j.jacep.2024.01.021

Vancouver

Raad M, Yogasundaram H, Oranefo J, Guandalini G, Markman T, Hyman M, et al. Class 1C Antiarrhythmics for Premature Ventricular Complex Suppression in Nonischemic Cardiomyopathy With Implantable Cardioverter-Defibrillators. JACC: Clinical Electrophysiology. 2024. doi:10.1016/j.jacep.2024.01.021

BibTeX
@article{Raad2024,
  author = {Raad, Mohamad and Yogasundaram, Haran and Oranefo, Justice and Guandalini, Gustavo and Markman, Timothy and Hyman, Matthew and Schaller, Robert and Supple, Gregory and Deo, Rajat and Nazarian, Saman and Riley, Michael and Lin, David and Garcia, Fermin and Dixit, Sanjay and Epstein, Andrew E and Callans, David and Marchlinski, Francis E and Frankel, David S},
  title = {Class 1C Antiarrhythmics for Premature Ventricular Complex Suppression in Nonischemic Cardiomyopathy With Implantable Cardioverter-Defibrillators},
  journal = {JACC: Clinical Electrophysiology},
  year = {2024},
  doi = {10.1016/j.jacep.2024.01.021}
}
Kostenlos starten →